Amryt Pharma
Amryt Pharma is an England-based pharmaceutical company that develops and commercializes therapeutics for the treatment of debilitating diseases.
Business Model:
Revenue: $243.5M
Employees: 201-500
Rankings
Industries / Tags:
Detailed Amryt Pharma Information
Geographic Data
Address: 196 High Road, Dept 920A
City: London
State: england
Zip: N22 8HH
Country: GB
Financial Info
Stage:
post ipo debt
Raised Last:
$125M
Raised Total:$146M
Social
Metrics
3,747,061Website Global Rank
3,446Website Monthly Traffic
Twitter Followers
Description
Amryt Pharma is an England-based pharmaceutical company that develops and commercializes therapeutics for the treatment of debilitating diseases.
Contact Phone:
Contact Email:
Amryt Pharma went public on 6/22/2012 on the London Stock Exchange
Listed Exchange:
London Stock Exchange
IPO Date:
6/22/2012
Ticker Symbol:
AMYT
Live
Opened: -/share
| EBITDA | - |
| Total Cash | - |
| Total Debt | - |
| Total Revenue | - |
| Total Profit (Gross) | - |
| PE Ratio | - |
| Announced Date | Company | Transaction | Money Raised |
|---|
| Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 6/2012 | IPO | - | 12/2018 | Grant | $9.6M | 12/2016 | Post-IPO Debt | $21.2M |
European Investment Bank |
12/2016 | Post-IPO Debt | 1 | $21.3M |
European Investment Bank European Investment Bank European Investment Bank European Investment Bank |
2/2022 | Post-IPO Debt | 1 | $125M |
Ares Management Ares Management |
6/2012 | IPO | - |
|---|
| Announced Date | Name | Price |
|---|---|---|
| 5/2021 | Chiasma | |
| 3/2019 | Aegerion Pharmaceuticals | |
| 5/2016 | Sompharmaceuticals |
Employee Departments
Employee States
|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|
